Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction
US4918165A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Jul 16, 1987 |
| Grant date | Apr 17, 1990 |
| Priority date | — |
| Expiry date | Jul 16, 2007 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/45
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A conjugated cytotoxin is provided for preventing posterior lens capsule opacification (after-cataract) after extracapsular extraction. Preferably, the mitotic inhibitor of lens epithelial cells comprises a conjugate containing methotrexate which is covalently linked to an antibody, such as anticollagen, in approximately a molar ratio of 1:1 to 10:1. The mitotic conjugate may be instilled in the anterior or posterior chamber of the eye, preferably immediately after the lens has been removed, or coated onto an intraocular lens prior to insertion onto the posterior lens capsule. Similar conjugates may be attached to other artificial materials in the body to fight fibroblast proliferation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.